Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic mice

Hepatology

Volumn 54, Issue 2, 2011, Pages 620-630

  Lin, Chih Wen ^a,b   Mars, Wendy M ^a   Paranjpe, Shirish ^a   Donthamsetty, Shashikiran ^a   Bhave, Vishakha S ^a   Kang, Liang I ^a   Orr, Anne ^a   Bowen, William C ^a   Bell, Aaron W ^a   Michalopoulos, George K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b E DA HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS [2 (3,5 DICHLOROPYRIDYLOXY)]BENZENE; DRINKING WATER; GLYPICAN 3; KI 67 ANTIGEN; PHENOBARBITAL; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HEPATOMEGALY; LIVER CELL; LIVER REGENERATION; MITOGENICITY; MOUSE; NONHUMAN; ORGAN WEIGHT; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; CELL PROLIFERATION; GENE EXPRESSION REGULATION; GENES, CDC; GLYPICANS; HEPATOCYTES; HEPATOMEGALY; MICE; MICE, TRANSGENIC; PHENOBARBITAL; PYRIDINES;

EID: 79960719528     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24417     Document Type: Review

References (38)

1. Fransson LA. Glypicans. Int J Biochem Cell Biol 2003; 35: 125-129.
2. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001; 108: 497-501.
3. Song HH, Filmus J. The role of glypicans in mammalian development. Biochim Biophys Acta 2002; 1573: 241-246.
4. Filmus J. Glypicans in growth control and cancer. Glycobiology 2001; 11: 19R-23R.
5. Iglesias BV, Centeno G, Pascuccelli H, Ward F, Peters MG, Filmus J, et al. Expression pattern of glypican-3 (GPC3) during human embryonic and fetal development. Histol Histopathol 2008; 23: 1333-1340.
6. Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, et al. Mutations in GPC3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat Genet 1996; 12: 241-247.
7. Neri G, Gurrieri F, Zanni G, Lin A. Clinical and molecular aspects of the Simpson-Golabi-Behmel syndrome. Am J Med Genet 1998; 79: 279-283.
8. Pellegrini M, Pilia G, Pantano S, Lucchini F, Uda M, Fumi M, et al. Gpc3 expression correlates with the phenotype of the Simpson-Golabi-Behmel syndrome. Dev Dyn 1998; 213: 431-439.
9. Cano-Gauci DF, Song HH, Yang H, McKerlie C, Choo B, Shi W, et al. Glypican-3-deficient mice exhibit developmental overgrowth and some of the abnormalities typical of Simpson-Golabi-Behmel syndrome. J Cell Biol 1999; 146: 255-264.
10. Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, et al. Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. HEPATOLOGY 2006; 44: 1012-1024.
11. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003; 125: 89-97.
12. Filmus J, Capurro M. Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diagn 2004; 8: 207-212.
13. Blanco-Bose WE, Murphy MJ, Ehninger A, Offner S, Dubey C, Huang W, et al. C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. HEPATOLOGY 2008; 48: 1302-1311.
14. Qatanani M, Moore DD. CAR, the continuously advancing receptor, in drug metabolism and disease. Curr Drug Metab 2005; 6: 329-339.
15. Wei P, Zhang J, Egan-Hafley M, Liang S, Moore DD. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000; 407: 920-923.
16. Columbano A, Shinozuka H. Liver regeneration versus direct hyperplasia. FASEB J 1996; 10: 1118-1128.
17. Diwan BA, Lubet RA, Ward JM, Hrabie JA, Rice JM. Tumor-promoting and hepatocarcinogenic effects of 1, 4-bis[2-(3, 5-dichloropyridyloxy)] benzene (TCPOBOP) in DBA/2NCr and C57BL/6NCr mice and an apparent promoting effect on nasal cavity tumors but not on hepatocellular tumors in F344/NCr rats initiated with N-nitrosodiethylamine. Carcinogenesis 1992; 13: 1893-1901.
18. Columbano A, Ledda-Columbano GM. Mitogenesis by ligands of nuclear receptors: an attractive model for the study of the molecular mechanisms implicated in liver growth. Cell Death Differ 2003; 10 Suppl 1: S19-21.
19. Ledda-Columbano GM, Pibiri M, Loi R, Perra A, Shinozuka H, Columbano A. Early increase in cyclin-D1 expression and accelerated entry of mouse hepatocytes into S phase after administration of the mitogen 1, 4-bis[2-(3, 5-dichloropyridyloxy)] benzene. Am J Pathol 2000; 156: 91-97.
20. Locker J, Tian J, Carver R, Concas D, Cossu C, Ledda-Columbano GM, et al. A common set of immediate-early response genes in liver regeneration and hyperplasia. HEPATOLOGY 2003; 38: 314-325.
21. Apte U, Gkretsi V, Bowen WC, Mars WM, Luo JH, Donthamsetty S, et al. Enhanced liver regeneration following changes induced by hepatocyte-specific genetic ablation of integrin-linked kinase. HEPATOLOGY 2009; 50: 844-851.
22. Donthamsetty S, Bowen W, Mars W, Bhave V, Luo JH, Wu C, et al. Liver-specific ablation of integrin-linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration. Toxicol Sci 2010; 113: 358-366.
23. Donthamsetty S, Bhave VS, Kliment CS, Bowen WC, Mars WM, Bell AW, et al. Excessive hepatomegaly of mice with hepatocyte-targeted elimination of integrin linked kinase following treatment with 1, 4-bis [2-(3, 5-dichaloropyridyloxy)] benzene. HEPATOLOGY 2011; 53: 587-595.
24. Liu B, Paranjpe S, Bowen WC, Bell AW, Luo JH, Yu YP, et al. Investigation of the role of glypican 3 in liver regeneration and hepatocyte proliferation. Am J Pathol 2009; 175: 717-724.
25. Liu B, Bell AW, Paranjpe S, Bowen WC, Khillan JS, Luo JH, et al. Suppression of liver regeneration and hepatocyte proliferation in hepatocyte-targeted glypican 3 transgenic mice. HEPATOLOGY 2010; 52: 1060-1067.
26. Ross PK, Woods CG, Bradford BU, Kosyk O, Gatti DM, Cunningham ML, et al. Time-course comparison of xenobiotic activators of CAR and PPARalpha in mouse liver. Toxicol Appl Pharmacol 2009; 235: 199-207.
27. Seewaldt VL, Dietze EC, Johnson BS, Collins SJ, Parker MB. Retinoic acid-mediated G1-S-phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression. Cell Growth Differ 1999; 10: 49-59.
28. Saucedo LJ, Edgar BA. Filling out the Hippo pathway. Nat Rev Mol Cell Biol 2007; 8: 613-621.
29. Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 2008; 20: 638-646.
30. Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213: 286-300.
31. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
32. Gao J, Chen Y, Wu KC, Liu J, Zhao YQ, Pan YL, et al. RUNX3 directly interacts with intracellular domain of Notch1 and suppresses Notch signaling in hepatocellular carcinoma cells. Exp Cell Res 2010; 316: 149-157.
33. Kohler C, Bell AW, Bowen WC, Monga SP, Fleig W, Michalopoulos GK. Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration. HEPATOLOGY 2004; 39: 1056-1065.
34. Grozdanov PN, Yovchev MI, Dabeva MD. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest 2006; 86: 1272-1284.
35. Michalopoulos GK. Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas. Am J Pathol 2010; 176: 2-13.
36. Mullany LK, White P, Hanse EA, Nelsen CJ, Goggin MM, Mullany JE, et al. Distinct proliferative and transcriptional effects of the D-type cyclins in vivo. Cell Cycle 2008; 7: 2215-2224.
37. Morgan DO. Principles of CDK regulation. Nature 1995; 374: 131-134.
38. Columbano A, Ledda-Columbano GM, Pibiri M, Concas D, Reddy JK, Rao MS. Peroxisome proliferator-activated receptor-alpha mice show enhanced hepatocyte proliferation in response to the hepatomitogen 1, 4-bis [2-(3, 5-dichloropyridyloxy)] benzene, a ligand of constitutive androstane receptor. HEPATOLOGY 2001; 34: 262-266.